SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
Public ClinicalTrials.gov record NCT06743126. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Prospective, Multicenter, Open-label, Randomized, Actively Controlled, Parallel-group Phase 3 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of IMA203 Versus Investigator's Choice of Treatment in Patients With Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (ACTengine® IMA203-301)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the recommended phase 2 dose versus investigator's choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma. For patients interested in additional information on how to participate, please follow this link: https://mytomorrows.com/trials/suprame/en-us/
Study identification
- NCT ID
- NCT06743126
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 360 participants
Conditions and interventions
Conditions
Interventions
- IMA203 Biological
- nivolumab plus relatlimab Biological
- lifileucel Biological
- nivolumab Biological
- pembrolizumab Biological
- ipilimumab Biological
- Dacarbazine Drug
- temozolomide Drug
- paclitaxel Drug
- paclitaxel plus carboplatin Drug
- Albumin-Bound Paclitaxel Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 13, 2025
- Primary completion
- Dec 31, 2027
- Completion
- Sep 30, 2031
- Last update posted
- Aug 17, 2026
2025 – 2031
United States locations
- U.S. sites
- 43
- U.S. states
- 25
- U.S. cities
- 38
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic | Phoenix | Arizona | 85054 | Recruiting |
| Honor Health Research Institute | Scottsdale | Arizona | 85258 | Recruiting |
| City of Hope National Medical Center | Duarte | California | 91010 | Recruiting |
| UC San Diego Moores Cancer Center | La Jolla | California | 92093 | Recruiting |
| UCLA Hematology/Oncology | Los Angeles | California | 90024 | Recruiting |
| UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco | California | 94143 | Recruiting |
| Stanford Cancer Center | Stanford | California | 94305 | Recruiting |
| University of Colorado, Anschutz Medical Campus | Aurora | Colorado | 80045 | Recruiting |
| Yale Cancer Center | New Haven | Connecticut | 06510 | Recruiting |
| Mayo Clinic Florida | Jacksonville | Florida | 32224 | Recruiting |
| University of Miami - Sylvester Comprehensive Cancer Cente | Miami | Florida | 33136 | Recruiting |
| AdventHealth, Orlando | Orlando | Florida | 32804 | Not yet recruiting |
| Moffitt Cancer Center | Tampa | Florida | 33612 | Recruiting |
| Winship Cancer Institute, Emory University | Atlanta | Georgia | 30322 | Not yet recruiting |
| University of Chicago Medical Center | Chicago | Illinois | 60637 | Recruiting |
| University of MD Greenebaum Comprehensive Cancer Center | Baltimore | Maryland | 21201 | Recruiting |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | Recruiting |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | Recruiting |
| University of Michigan | Ann Arbor | Michigan | 48109 | Recruiting |
| Mayo Clinic | Rochester | Minnesota | 55905 | Recruiting |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | Recruiting |
| Atlantic Health System/Morristown Medical Center | Morristown | New Jersey | 07960 | Recruiting |
| Laura and Isaac Perlmutter Cancer Center at NYU Langone Health | New York | New York | 10016 | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | Recruiting |
| University of Rochester | Rochester | New York | 14642 | Recruiting |
| UNC Hospitals, The University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27599 | Recruiting |
| Cleveland Clinic, Taussig Cancer Institute | Cleveland | Ohio | 44195 | Recruiting |
| Ohio State University | Columbus | Ohio | 43210 | Recruiting |
| Providence Cancer Institute Franz Clinic | Portland | Oregon | 97213 | Recruiting |
| Lehigh Valley Topper Cancer Institute | Allentown | Pennsylvania | 18103 | Recruiting |
| University of Pennsylvania, Abramson Cancer Center | Philadelphia | Pennsylvania | 19104 | Recruiting |
| Thomas Jeffersion University, Sidney Kimmel Cancer Center | Philadelphia | Pennsylvania | 19107 | Recruiting |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | Recruiting |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | Recruiting |
| Avera Cancer Institute | Sioux Falls | South Dakota | 57105 | Recruiting |
| SCRI Oncology Partners | Nashville | Tennessee | 37203 | Recruiting |
| Baylor University | Dallas | Texas | 75246 | Recruiting |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
| Huntsman Cancer Institute, University of Utah | Salt Lake City | Utah | 84112 | Recruiting |
| Virginia Commonwealth University | Richmond | Virginia | 23219 | Recruiting |
| Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | Recruiting |
| University of Wisconsin | Madison | Wisconsin | 53792 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 28 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06743126, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 17, 2026 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06743126 live on ClinicalTrials.gov.